NCT02808208 - Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

End Stage Renal Disease (ESRD)Vascular Access Complication

Interventions

BIOLOGICAL

Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)

A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.

DRUG

Placebo

5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.

BIOLOGICAL

Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)

Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester